ENDRA Life Sciences Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名208/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价30.00。中期看,股价处于平稳状态。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
ENDRA Life Sciences Inc评分
相关信息
行业排名
208 / 404
全市场排名
374 / 4562
所属行业
生物技术与医疗研究
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
30.000
目标均价
+447.45%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
ENDRA Life Sciences Inc亮点
亮点风险
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
公司代码NDRA
公司ENDRA Life Sciences Inc
CEOTokman (Alexander Y)
网址https://www.endrainc.com/
常见问题
ENDRA Life Sciences Inc(NDRA)的当前股价是多少?
ENDRA Life Sciences Inc(NDRA)的当前股价是 5.100。
ENDRA Life Sciences Inc的股票代码是什么?
ENDRA Life Sciences Inc的股票代码是NDRA。
ENDRA Life Sciences Inc股票的52周最高点是多少?
ENDRA Life Sciences Inc股票的52周最高点是11.960。
ENDRA Life Sciences Inc股票的52周最低点是多少?
ENDRA Life Sciences Inc股票的52周最低点是2.900。
ENDRA Life Sciences Inc的市值是多少?
ENDRA Life Sciences Inc的市值是4.01M。
ENDRA Life Sciences Inc的净利润是多少?
ENDRA Life Sciences Inc的净利润为-11.51M。
现在ENDRA Life Sciences Inc(NDRA)的股票是买入、持有还是卖出?
根据分析师评级,ENDRA Life Sciences Inc(NDRA)的总体评级为买入,目标价格为30.000。
ENDRA Life Sciences Inc(NDRA)股票的每股收益(EPS TTM)是多少
ENDRA Life Sciences Inc(NDRA)股票的每股收益(EPS TTM)是2812.223。